Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics develops conditionally activated therapeutics engineered to stimulate the immune system for cancer and other immune-mediated conditions. News about HOWL centers on the company’s PREDATOR platform, INDUKINE molecules, INDUCER T cell engager work, and programs such as WTX-124 and WTX-330.
Recurring updates include clinical and preclinical data presentations, FDA regulatory designations, operating and financial results, program licensing or asset-rights activity, capital-structure actions, shareholder voting matters, and corporate-strategy updates tied to the company’s oncology-focused development pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Werewolf Therapeutics (Nasdaq: HOWL) announced the publication of preclinical data for mWTX-330, an Interleukin-12 INDUKINE molecule, in Cancer Immunology Research. This study demonstrates that mWTX-330 effectively stimulates an anti-tumor immune response by selectively delivering IL-12 to the tumor microenvironment while minimizing systemic toxicity. Key findings include robust immune activation in multiple tumor models and improved T-cell activity without signs of exhaustion. The company is preparing for a Phase 1 clinical trial for WTX-330 in patients with advanced solid tumors or lymphoma resistant to checkpoint inhibitors. The trial aims to evaluate safety and efficacy, marking a significant step in Werewolf's mission to enhance cancer treatments through targeted immune activation.
Werewolf Therapeutics (Nasdaq: HOWL) announced significant advancements in its clinical trials and financial position. The company is preparing to release initial clinical data for its IL-2 INDUKINE WTX-124 monotherapy in Q4 2023, while the first patient has been dosed in the IL-12 INDUKINE WTX-330 trial. Furthermore, it nominated WTX-712 for preclinical development. The financial update shows a cash position of $129.3 million, with guidance extended to cover operations through Q4 2024. Collaboration revenue rose to $7.3 million in Q4 2022, a notable increase from 2021, amidst rising expenses primarily related to R&D.
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the publication of abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. Key presentations include:
- Abstract 1829: Generation of IL-21 INDUKINE™ molecules for cancer treatment on April 17, 9:00 a.m. - 12:30 p.m.
- Abstract CT133: Phase 1/1b study of WTX-124, April 17, 1:30 p.m. - 5:00 p.m.
- Abstract CT254: First-in-human study of WTX-330 on April 18, 1:30 p.m. - 5:00 p.m.
Werewolf is focused on conditionally activated therapeutics to enhance the immune response against cancer.
Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The abstract, numbered 1829, details the generation of IL-21 INDUKINE™ molecules aimed at activating the immune system while minimizing side effects. The presentation will occur on April 17 from 9:00 a.m. to 12:30 p.m. at Poster Section 24, Board Number 1. The company utilizes its proprietary PREDATOR™ platform to develop conditionally activated therapeutics targeting solid tumors, including its lead candidates, WTX-124 and WTX-330.